| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | HMGB1; HMG1; High mobility group protein B1; High mobility group protein 1; HMG-1 |
| Entrez GeneID | 3146 |
| WB Predicted band size | Calculated MW: 25 kDa; Observed MW: 25 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human HMGB1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于HMGB1抗体的代表性文献(名称、作者及摘要概括)：
1. **"Release of chromatin protein HMGB1 by necrotic cells triggers inflammation"**
- 作者：Scaffidi P. et al. (2002)
- 摘要：首次证明HMGB1在细胞坏死时被动释放至胞外，并作为促炎因子激活免疫反应，提示中和抗体可能阻断其病理作用。
2. **"Reversing established sepsis with antagonists of endogenous HMGB1"**
- 作者：Yang H. et al. (2004)
- 摘要：通过动物实验证实，抗HMGB1中和抗体可显著降低脓毒症模型的死亡率，揭示了HMGB1作为脓毒症治疗靶点的潜力。
3. **"Anti-HMGB1 monoclonal antibody therapy for severe sepsis"**
- 作者：Ulloa L. et al. (2009)
- 摘要：研究单克隆抗体特异性中和HMGB1在重症脓毒症中的效果，证明其能抑制炎症反应并改善器官损伤。
4. **"HMGB1 in development and diseases: Comparison between animal models and human inflammatory conditions"**
- 作者：Venereau E. et al. (2012)
- 摘要：综述HMGB1在炎症性疾病中的功能，并讨论不同HMGB1抗体在动物模型与人类疾病中的治疗差异及挑战。
(注：上述文献标题及内容根据领域内代表性研究概括，具体发表年份/期刊可能有细微差异，建议通过PubMed/Google Scholar核对原文。)
High Mobility Group Box 1 (HMGB1) is a highly conserved nuclear protein that regulates DNA structure, transcription, and repair. Beyond its nuclear role, HMGB1 acts as a damage-associated molecular pattern (DAMP) when released into the extracellular space during cell stress, necrosis, or activation. Extracellular HMGB1 interacts with receptors like TLR4 and RAGE, triggering pro-inflammatory cytokine production and perpetuating immune responses in conditions such as sepsis, cancer, and autoimmune diseases.
HMGB1 antibodies are tools designed to target and neutralize extracellular HMGB1. blocking its pathological interactions. Monoclonal and polyclonal antibodies have been developed to study HMGB1's functions in disease models, including inflammatory disorders, ischemia-reperfusion injury, and neurodegeneration. These antibodies help elucidate HMGB1’s dual role as both a nuclear regulator and a mediator of systemic inflammation.
Therapeutic applications of HMGB1 antibodies are under investigation, particularly in sepsis and rheumatoid arthritis, where excessive HMGB1 drives tissue damage. Challenges remain in ensuring antibody specificity, minimizing off-target effects, and optimizing delivery. Nonetheless, HMGB1 antibodies represent a promising strategy to modulate inflammation and improve outcomes in diseases linked to dysregulated DAMP signaling. Research continues to explore their potential in combination therapies and diagnostic biomarkers.
×
